[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021,71(3):209-249.
[2] Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37513025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J]. Lancet, 2018, 391(10125):1023-1075.
[3] Wang C H, Wey K C, Mo L R, et al. Current trends and recent advances in diagnosis, therapy, and prevention of hepatocellular carcinoma[J]. Asian Pac J Cancer Prev, 2015,16(9):3595-604.
[4] Wang M, Wang Y, Feng X, et al. Contribution of hepatitis B virus and hepatitis C virus to liver cancer in China north areas: experience of the Chinese National Cancer Center[J]. Int J Infect Dis, 2017, 65:15-21.
[5] Liu K, Choi J, Le A, et al. Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis[J]. Aliment Pharmacol Ther, 2019, 50(9):1037-1048.
[6] Wong G L, Wong V W. Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy[J]. World J Gastroenterol, 2013, 19(39):6515-6522.
[7] Wong V W, Chan S L, Mo F, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers[J]. J Clin Oncol, 2010, 28(10):1660-1665.
[8] Yuen M F, Tanaka Y, Fong D Y, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B[J]. J Hepatol, 2009, 50(1):80-8.
[9] Wong G L, Chan H L, Wong C K, et al. Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B[J]. J Hepatol, 2014, 60(2):339-345.
[10] Yang H I, Yuen M F, Chan H L, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score[J]. Lancet Oncol, 2011, 12(6):568-574.
[11] Jung K S, Kim S U, Song K, et al. Validation of hepatitis B virus-related hepatocellular carcinoma prediction models in the era of antiviral therapy[J]. Hepatology, 2015, 62(6):1757-1766.
[12] Seo Y S, Jang B K, Um S H, et al. Validation of risk prediction models for the development of HBV-related HCC: a retrospective multi-center 10-year follow-up cohort study[J]. Oncotarget, 2017, 8(68):113213-113224.
[13] Papatheodoridis G, Dalekos G, Sypsa V, et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy[J]. J Hepatol, 2016, 64(4):800-806.
[14] Kim M N, Hwang S G, Rim K S, et al. Validation of PAGE-B model in Asian chronic hepatitis B patients receiving entecavir or tenofovir[J]. Liver Int, 2017, (12):1788-1795.
[15] Kim J H, Kim Y D, Lee M, et al. Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy[J]. J Hepatol, 2018, 69(5):1066-1073.
[16] Yip T C, Wong G L, Wong V W, et al. Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B[J]. J Hepatol, 2020, 72(5):847-854.
[17] Hsu Y C, Yip T C, Ho H J, et al. Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B[J]. J Hepatol, 2018, 69(2):278-285.
[18] Kim S U, Seo Y S, Lee H A, et al. Validation of the CAMD score in patients with chronic hepatitis B virus infection receiving antiviral therapy[J]. Clin Gastroenterol Hepatol, 2020, 18(3):693-699.
[19] Papatheodoridis G V, Sypsa V,et al. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B[J]. J Hepatol, 2020, 72(6):1088-1096.
[20] Yang H I, Yeh M L, Wong G L, et al. Real-world effectiveness from the Asia Pacific Rim Liver Consortium for HBV risk score for the prediction of hepatocellular carcinoma in chronic hepatitis B patients treated with oral antiviral therapy[J]. J Infect Dis, 2020, 221(3):389-399.
[21] Sharma S A, Kowgier M, Hansen B E, et al. Toronto HCC risk index: a validated scoring system to predict 10-year risk of HCC in patients with cirrhosis[J]. J Hepatol, 2017, S0168-8278(17)32248-1.
[22] Åström H, Ndegwa N, Hagstr?m H. External validation of the Toronto hepatocellular carcinoma risk index in a Swedish population[J]. JHEP Rep, 2021, 3(5):100343.
[23] Zhang H, Zhu J, Xi L, et al. Validation of the Toronto hepatocellular carcinoma risk index for patients with cirrhosis in China: a retrospective cohort study[J]. World J Surg Oncol, 2019, 17(1):75.
[24] 中华预防医学会肝胆胰疾病预防与控制专业委员会,中国研究型医院学会肝病专业委员会,中华医学会肝病学分会,等. 原发性肝癌的分层筛查与监测指南(2020版) [J]. 临床肝胆病杂志, 2021,37(2):286-295.
[25] Fan R, Papatheodoridis G, Sun J, et al. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis[J]. J Hepatol, 2020, 73(6):1368-1378.
[26] Yamashita Y, Joshita S, Sugiura A, et al. aMAP score prediction of hepatocellular carcinoma occurrence and incidence-free rate after a sustained virologic response in chronic hepatitis C[J]. Hepatol Res, 2021, 51(9):933-942.
[27] Innes H, Jepsen P, McDonald S, et al. Performance of models to predict hepatocellular carcinoma risk among UK patients with cirrhosis and cured HCV infection[J]. JHEP Rep, 2021, 3(6):100384.
[28] Yang Y, Zhou Y, Zhang X, et al. Using the aMAP risk score to predict late recurrence following radiofrequency ablation for hepatocellular carcinoma in Chinese population: a multicenter study[J]. J Hepatocell Carcinoma, 2021, 8:837-850.
[29] Sun Y, Li Z, Liao G, et al. aMAP score as a predictor for long-term outcomes in patients with HBV-related acute-on-chronic liver failure[J]. Int J Gen Med, 2022, 15:407-415.
[30] 国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版)[J]. 临床肝胆病杂志,2022,38(2):288-303.
[31] Sohn W, Cho J Y, Kim J H, et al. Risk score model for the development of hepatocellular carcinoma in treatment-na?ve patients receiving oral antiviral treatment for chronic hepatitis B[J]. Clin Mol Hepatol, 2017, 23(2):170-178. |
